<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD07290000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P01130</UniProt_ID>
  <Seq_Length>860</Seq_Length>
  <Molecule_Weight>95376</Molecule_Weight>
  <KEGG_ID>hsa:3949</KEGG_ID>
  <Orthology_ID>K12473</Orthology_ID>
  <Function_Summary>Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. In case of HIV-1 infection, functions as a receptor for extracellular Tat in neurons, mediating its internalization in uninfected cells.</Function_Summary>
  <Pfam_ID>PF07645:EGF_CA@@PF00057:Ldl_recept_a@@PF00058:Ldl_recept_b</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>LDL receptor</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with a very-low-density lipoprotein particle to initiate a change in cell activity.</Detail>
      <Keyword>Very-low-density lipoprotein particle receptor activity</Keyword>
      <Ontology_ID>GO:0030229</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with calcium ions (Ca2+).</Detail>
      <Keyword>Calcium ion binding</Keyword>
      <Ontology_ID>GO:0005509</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a glycoprotein, a protein that contains covalently bound glycose (monosaccharide) residues. These also include proteoglycans.</Detail>
      <Keyword>Glycoprotein binding</Keyword>
      <Ontology_ID>GO:0001948</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with a low-density lipoprotein particle to initiate a change in cell activity.</Detail>
      <Keyword>Low-density lipoprotein receptor activity</Keyword>
      <Ontology_ID>GO:0005041</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>286</Position>
      <Original>Ser</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>356</Position>
      <Original>Asp</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>221</Position>
      <Original>Asp</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>526</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>224</Position>
      <Original>Asp</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>116</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>342</Position>
      <Original>Asp</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>649</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>677</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>95</Position>
      <Original>Cys</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>168</Position>
      <Original>Asp</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>434</Position>
      <Original>Thr</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>101</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>414</Position>
      <Original>Leu</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>175</Position>
      <Original>Asp</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>568</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>667</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>433</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>318</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>270</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>714</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>177</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>313</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>27</Position>
      <Original>Cys</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>288</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>168</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>633</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>826</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>248</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>335</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>304</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>201</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>172</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>248</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>140</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>266</Position>
      <Original>Asp</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>52</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>277</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>350</Position>
      <Original>Arg</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>173</Position>
      <Original>Cys</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>416</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>240</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>408</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>224</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>329</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>443</Position>
      <Original>Trp</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>579</Position>
      <Original>Asp</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>391</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>564</Position>
      <Original>Asn</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>700</Position>
      <Original>Asp</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>173</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>90</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>155</Position>
      <Original>Cys</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>366</Position>
      <Original>Gln</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>46</Position>
      <Original>Cys</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>415</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>797</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>814</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>354</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>228</Position>
      <Original>Glu</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>483</Position>
      <Original>Trp</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>549</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>175</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>139</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>338</Position>
      <Original>Cys</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>184</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>416</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>342</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>231</Position>
      <Original>Cys</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>90</Position>
      <Original>Asp</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>50</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>261</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>109</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>370</Position>
      <Original>Asn</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>168</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>608</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>828</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>197</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>441</Position>
      <Original>Ile</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>441</Position>
      <Original>Ile</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>352</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>423</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>329</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>682</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>399</Position>
      <Original>Ala</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>401</Position>
      <Original>Leu</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>592</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>429</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>134</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>792</Position>
      <Original>Ile</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>482</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>92</Position>
      <Original>Gln</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>343</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>406</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>844</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>301</Position>
      <Original>Asp</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>253</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>227</Position>
      <Original>Asp</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>523</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>471</Position>
      <Original>Arg</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>354</Position>
      <Original>Asp</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>565</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>221</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>134</Position>
      <Original>Cys</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>468</Position>
      <Original>Val</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>228</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>221</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>197</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>222</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>379</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>87</Position>
      <Original>Trp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>485</Position>
      <Original>His</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>56</Position>
      <Original>Ser</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>358</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>357</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>546</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>364</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>318</Position>
      <Original>Cys</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>304</Position>
      <Original>Asp</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>827</Position>
      <Original>Val</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>302</Position>
      <Original>Cys</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>685</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>276</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>478</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>306</Position>
      <Original>Ser</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>564</Position>
      <Original>Asn</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>368</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>726</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>699</Position>
      <Original>Pro</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>451</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>599</Position>
      <Original>Leu</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>302</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>379</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>579</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>327</Position>
      <Original>His</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>90</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>2</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>254</Position>
      <Original>Gln</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>403</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>160</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>89</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>432</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>224</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>197</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>105</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>226</Position>
      <Original>Ser</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>276</Position>
      <Original>Cys</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>318</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>255</Position>
      <Original>Cys</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>78</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>431</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>256</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>479</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>401</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process involved in the maintenance of an internal steady state of cholesterol within an organism or cell.</Detail>
      <Keyword>Cholesterol homeostasis</Keyword>
      <Ontology_ID>GO:0042632</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a low-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded.</Detail>
      <Keyword>Low-density lipoprotein particle clearance</Keyword>
      <Ontology_ID>GO:0034383</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of phospholipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Phospholipids are any lipids containing phosphoric acid as a mono- or diester.</Detail>
      <Keyword>Phospholipid transport</Keyword>
      <Ontology_ID>GO:0015914</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent. Includes fatty acids; neutral fats, other fatty-acid esters, and soaps; long-chain (fatty) alcohols and waxes; sphingoids and other long-chain bases; glycolipids, phospholipids and sphingolipids; and carotenes, polyprenols, sterols, terpenes and other isoprenoids.</Detail>
      <Keyword>Lipid metabolic process</Keyword>
      <Ontology_ID>GO:0006629</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, or within a multicellular organism by means of some agent such as a transporter or pore.</Detail>
      <Keyword>Transport</Keyword>
      <Ontology_ID>GO:0006810</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of cholesterol into a cell or organelle.</Detail>
      <Keyword>Cholesterol import</Keyword>
      <Ontology_ID>GO:0070508</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones. It is a component of the plasma membrane lipid bilayer and of plasma lipoproteins and can be found in all animal tissues.</Detail>
      <Keyword>Cholesterol metabolic process</Keyword>
      <Ontology_ID>GO:0008203</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus.</Detail>
      <Keyword>Steroid metabolic process</Keyword>
      <Ontology_ID>GO:0008202</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the rate, frequency or extent of phosphatidylcholine catabolism. Phosphatidylcholine catabolic processes are the chemical reactions and pathways resulting in the breakdown of phosphatidylcholines, any of a class of glycerophospholipids in which the phosphatidyl group is esterified to the hydroxyl group of choline.</Detail>
      <Keyword>Regulation of phosphatidylcholine catabolic process</Keyword>
      <Ontology_ID>GO:0010899</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Uptake of cholesterol into the blood by absorption from the small intestine.</Detail>
      <Keyword>Intestinal cholesterol absorption</Keyword>
      <Ontology_ID>GO:0030299</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A vesicle-mediated transport process in which cells take up external materials or membrane constituents by the invagination of a small region of the plasma membrane to form a new membrane-bounded vesicle.</Detail>
      <Keyword>Endocytosis</Keyword>
      <Ontology_ID>GO:0006897</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process in which an organism has an effect on an organism of a different species.</Detail>
      <Keyword>Interspecies interaction between organisms</Keyword>
      <Ontology_ID>GO:0044419</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate, frequency, or extent of triglyceride biosynthesis. Triglyceride biosynthesis is the collection of chemical reactions and pathways resulting in the formation of triglyceride, any triester of glycerol.</Detail>
      <Keyword>Positive regulation of triglyceride biosynthetic process</Keyword>
      <Ontology_ID>GO:0010867</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving any conjugated, water-soluble protein in which the nonprotein group consists of a lipid or lipids.</Detail>
      <Keyword>Lipoprotein metabolic process</Keyword>
      <Ontology_ID>GO:0042157</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of lipids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Lipids are compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.</Detail>
      <Keyword>Lipid transport</Keyword>
      <Ontology_ID>GO:0006869</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>845</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>847</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MGPWGWKLRWTVALLLAAAGTAVGDRCERNEFQCQDGKCISYKWVCDGSAECQDGSDESQETCLSVTCKSGDFSCGGRVNRCIPQFWRCDGQVDCDNGSDEQGCPPKTCSQDEFRCHDGKCISRQFVCDSDRDCLDGSDEASCPVLTCGPASFQCNSSTCIPQLWACDNDPDCEDGSDEWPQRCRGLYVFQGDSSPCSAFEFHCLSGECIHSSWRCDGGPDCKDKSDEENCAVATCRPDEFQCSDGNCIHGSRQCDREYDCKDMSDEVGCVNVTLCEGPNKFKCHSGECITLDKVCNMARDCRDWSDEPIKECGTNECLDNNGGCSHVCNDLKIGYECLCPDGFQLVAQRRCEDIDECQDPDTCSQLCVNLEGGYKCQCEEGFQLDPHTKACKAVGSIAYLFFTNRHEVRKMTLDRSEYTSLIPNLRNVVALDTEVASNRIYWSDLSQRMICSTQLDRAHGVSSYDTVISRDIQAPDGLAVDWIHSNIYWTDSVLGTVSVADTKGVKRKTLFRENGSKPRAIVVDPVHGFMYWTDWGTPAKIKKGGLNGVDIYSLVTENIQWPNGITLDLLSGRLYWVDSKLHSISSIDVNGGNRKTILEDEKRLAHPFSLAVFEDKVFWTDIINEAIFSANRLTGSDVNLLAENLLSPEDMVLFHNLTQPRGVNWCERTTLSNGGCQYLCLPAPQINPHSPKFTCACPDGMLLARDMRSCLTEAEAAVATQETSTVRLKVSSTAVRTQHTTTRPVPDTSRLPGATPGLTTVEIVTMSHQALGDVAGRGNEKKPSSVRALSIVLPIVLLVFLCLGVFLLWKNWRLKNINSINFDNPVYQKTTEDEVHICHNQDGYSYPSRQMVSLEDDVA</Protein_Seq>
    <DNA_Seq>CTCTTGCAGTGAGGTGAAGACATTTGAAAATCACCCCACTGCAAACTCCTCCCCCTGCTAGAAACCTCACATTGAAATGCTGTAAATGACGTGGGCCCCGAGTGCAATCGCGGGAAGCCAGGGTTTCCAGCTAGGACACAGCAGGTCGTGATCCGGGTCGGGACACTGCCTGGCAGAGGCTGCGAGCATGGGGCCCTGGGGCTGGAAATTGCGCTGGACCGTCGCCTTGCTCCTCGCCGCGGCGGGGACTGCAGTGGGCGACAGATGCGAAAGAAACGAGTTCCAGTGCCAAGACGGGAAATGCATCTCCTACAAGTGGGTCTGCGATGGCAGCGCTGAGTGCCAGGATGGCTCTGATGAGTCCCAGGAGACGTGCTTGTCTGTCACCTGCAAATCCGGGGACTTCAGCTGTGGGGGCCGTGTCAACCGCTGCATTCCTCAGTTCTGGAGGTGCGATGGCCAAGTGGACTGCGACAACGGCTCAGACGAGCAAGGCTGTCCCCCCAAGACGTGCTCCCAGGACGAGTTTCGCTGCCACGATGGGAAGTGCATCTCTCGGCAGTTCGTCTGTGACTCAGACCGGGACTGCTTGGACGGCTCAGACGAGGCCTCCTGCCCGGTGCTCACCTGTGGTCCCGCCAGCTTCCAGTGCAACAGCTCCACCTGCATCCCCCAGCTGTGGGCCTGCGACAACGACCCCGACTGCGAAGATGGCTCGGATGAGTGGCCGCAGCGCTGTAGGGGTCTTTACGTGTTCCAAGGGGACAGTAGCCCCTGCTCGGCCTTCGAGTTCCACTGCCTAAGTGGCGAGTGCATCCACTCCAGCTGGCGCTGTGATGGTGGCCCCGACTGCAAGGACAAATCTGACGAGGAAAACTGCGCTGTGGCCACCTGTCGCCCTGACGAATTCCAGTGCTCTGATGGAAACTGCATCCATGGCAGCCGGCAGTGTGACCGGGAATATGACTGCAAGGACATGAGCGATGAAGTTGGCTGCGTTAATGTGACACTCTGCGAGGGACCCAACAAGTTCAAGTGTCACAGCGGCGAATGCATCACCCTGGACAAAGTCTGCAACATGGCTAGAGACTGCCGGGACTGGTCAGATGAACCCATCAAAGAGTGCGGGACCAACGAATGCTTGGACAACAACGGCGGCTGTTCCCACGTCTGCAATGACCTTAAGATCGGCTACGAGTGCCTGTGCCCCGACGGCTTCCAGCTGGTGGCCCAGCGAAGATGCGAAGATATCGATGAGTGTCAGGATCCCGACACCTGCAGCCAGCTCTGCGTGAACCTGGAGGGTGGCTACAAGTGCCAGTGTGAGGAAGGCTTCCAGCTGGACCCCCACACGAAGGCCTGCAAGGCTGTGGGCTCCATCGCCTACCTCTTCTTCACCAACCGGCACGAGGTCAGGAAGATGACGCTGGACCGGAGCGAGTACACCAGCCTCATCCCCAACCTGAGGAACGTGGTCGCTCTGGACACGGAGGTGGCCAGCAATAGAATCTACTGGTCTGACCTGTCCCAGAGAATGATCTGCAGCACCCAGCTTGACAGAGCCCACGGCGTCTCTTCCTATGACACCGTCATCAGCAGAGACATCCAGGCCCCCGACGGGCTGGCTGTGGACTGGATCCACAGCAACATCTACTGGACCGACTCTGTCCTGGGCACTGTCTCTGTTGCGGATACCAAGGGCGTGAAGAGGAAAACGTTATTCAGGGAGAACGGCTCCAAGCCAAGGGCCATCGTGGTGGATCCTGTTCATGGCTTCATGTACTGGACTGACTGGGGAACTCCCGCCAAGATCAAGAAAGGGGGCCTGAATGGTGTGGACATCTACTCGCTGGTGACTGAAAACATTCAGTGGCCCAATGGCATCACCCTAGATCTCCTCAGTGGCCGCCTCTACTGGGTTGACTCCAAACTTCACTCCATCTCAAGCATCGATGTCAACGGGGGCAACCGGAAGACCATCTTGGAGGATGAAAAGAGGCTGGCCCACCCCTTCTCCTTGGCCGTCTTTGAGGACAAAGTATTTTGGACAGATATCATCAACGAAGCCATTTTCAGTGCCAACCGCCTCACAGGTTCCGATGTCAACTTGTTGGCTGAAAACCTACTGTCCCCAGAGGATATGGTTCTCTTCCACAACCTCACCCAGCCAAGAGGAGTGAACTGGTGTGAGAGGACCACCCTGAGCAATGGCGGCTGCCAGTATCTGTGCCTCCCTGCCCCGCAGATCAACCCCCACTCGCCCAAGTTTACCTGCGCCTGCCCGGACGGCATGCTGCTGGCCAGGGACATGAGGAGCTGCCTCACAGAGGCTGAGGCTGCAGTGGCCACCCAGGAGACATCCACCGTCAGGCTAAAGGTCAGCTCCACAGCCGTAAGGACACAGCACACAACCACCCGACCTGTTCCCGACACCTCCCGGCTGCCTGGGGCCACCCCTGGGCTCACCACGGTGGAGATAGTGACAATGTCTCACCAAGCTCTGGGCGACGTTGCTGGCAGAGGAAATGAGAAGAAGCCCAGTAGCGTGAGGGCTCTGTCCATTGTCCTCCCCATCGTGCTCCTCGTCTTCCTTTGCCTGGGGGTCTTCCTTCTATGGAAGAACTGGCGGCTTAAGAACATCAACAGCATCAACTTTGACAACCCCGTCTATCAGAAGACCACAGAGGATGAGGTCCACATTTGCCACAACCAGGACGGCTACAGCTACCCCTCGAGACAGATGGTCAGTCTGGAGGATGACGTGGCGTGAACATCTGCCTGGAGTCCCGTCCCTGCCCAGAACCCTTCCTGAGACCTCGCCGGCCTTGTTTTATTCAAAGACAGAGAAGACCAAAGCATTGCCTGCCAGAGCTTTGTTTTATATATTTATTCATCTGGGAGGCAGAACAGGCTTCGGACAGTGCCCATGCAATGGCTTGGGTTGGGATTTTGGTTTCTTCCTTTCCTCGTGAAGGATAAGAGAAACAGGCCCGGGGGGACCAGGATGACACCTCCATTTCTCTCCAGGAAGTTTTGAGTTTCTCTCCACCGTGACACAATCCTCAAACATGGAAGATGAAAGGGGAGGGGATGTCAGGCCCAGAGAAGCAAGTGGCTTTCAACACACAACAGCAGATGGCACCAACGGGACCCCCTGGCCCTGCCTCATCCACCAATCTCTAAGCCAAACCCCTAAACTCAGGAGTCAACGTGTTTACCTCTTCTATGCAAGCCTTGCTAGACAGCCAGGTTAGCCTTTGCCCTGTCACCCCCGAATCATGACCCACCCAGTGTCTTTCGAGGTGGGTTTGTACCTTCCTTAAGCCAGGAAAGGGATTCATGGCGTCGGAAATGATCTGGCTGAATCCGTGGTGGCACCGAGACCAAACTCATTCACCAAATGATGCCACTTCCCAGAGGCAGAGCCTGAGTCACTGGTCACCCTTAATATTTATTAAGTGCCTGAGACACCCGGTTACCTTGGCCGTGAGGACACGTGGCCTGCACCCAGGTGTGGCTGTCAGGACACCAGCCTGGTGCCCATCCTCCCGACCCCTACCCACTTCCATTCCCGTGGTCTCCTTGCACTTTCTCAGTTCAGAGTTGTACACTGTGTACATTTGGCATTTGTGTTATTATTTTGCACTGTTTTCTGTCGTGTGTGTTGGGATGGGATCCCAGGCCAGGGAAAGCCCGTGTCAATGAATGCCGGGGACAGAGAGGGGCAGGTTGACCGGGACTTCAAAGCCGTGATCGTGAATATCGAGAACTGCCATTGTCGTCTTTATGTCCGCCCACCTAGTGCTTCCACTTCTATGCAAATGCCTCCAAGCCATTCACTTCCCCAATCTTGTCGTTGATGGGTATGTGTTTAAAACATGCACGGTGAGGCCGGGCGCAGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGTGGATCATGAGGTCAGGAGATCGAGACCATCCTGGCTAACACGTGAAACCCCGTCTCTACTAAAAATACAAAAAATTAGCCGGGCGTGGTGGCGGGCACCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATGGTGTGAACCCGGGAAGCGGAGCTTGCAGTGAGCCGAGATTGCGCCACTGCAGTCCGCAGTCTGGCCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAACAAAAAAAAACCATGCATGGTGCATCAGCAGCCCATGGCCTCTGGCCAGGCATGGCGAGGCTGAGGTGGGAGGATGGTTTGAGCTCAGGCATTTGAGGCTGTCGTGAGCTATGATTATGCCACTGCTTTCCAGCCTGGGCAACATAGTAAGACCCCATCTCTTAAAAAATGAATTTGGCCAGACACAGGTGCCTCACGCCTGTAATCCCAGCACTTTGGGAGGCTGAGCTGGATCACTTGAGTTCAGGAGTTGGAGACCAGGCCTGAGCAACAAAGCGAGATCCCATCTCTACAAAAACCAAAAAGTTAAAAATCAGCTGGGTACGGTGGCACGTGCCTGTGATCCCAGCTACTTGGGAGGCTGAGGCAGGAGGATCGCCTGAGCCCAGGAGGTGGAGGTTGCAGTGAGCCATGATCGAGCCACTGCACTCCAGCCTGGGCAACAGATGAAGACCCTATTTCAGAAATACAACTATAAAAAAATAAATAAATCCTCCAGTCTGGATCGTTTGACGGGACTTCAGGTTCTTTCTGAAATCGCCGTGTTACTGTTGCACTGATGTCCGGAGAGACAGTGACAGCCTCCGTCAGACTCCCGCGTGAAGATGTCACAAGGGATTGGCAATTGTCCCCAGGGACAAAACACTGTGTCCCCCCCAGTGCAGGGAACCGTGATAAGCCTTTCTGGTTTCGGAGCACGTAAATGCGTCCCTGTACAGATAGTGGGGATTTTTTGTTATGTTTGCACTTTGTATATTGGTTGAAACTGTTATCACTTATATATATATATATACACACATATATATAAAATCTATTTATTTTTGCAAACCCTGGTTGCTGTATTTGTTCAGTGACTATTCTCGGGGCCCTGTGTAGGGGGTTATTGCCTCTGAAATGCCTCTTCTTTATGTACAAAGATTATTTGCACGAACTGGACTGTGTGCAACGCTTTTTGGGAGAATGATGTCCCCGTTGTATGTATGAGTGGCTTCTGGGAGATGGGTGTCACTTTTTAAACCACTGTATAGAAGGTTTTTGTAGCCTGAATGTCTTACTGTGATCAATTAAATTTCTTAAATGAACCAATTTGTCTAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Lysosome</CellLocal>
      <Ontology_ID>GO:0005764</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Integral to plasma membrane</CellLocal>
      <Ontology_ID>GO:0005887</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Clathrin-coated endocytic vesicle membrane</CellLocal>
      <Ontology_ID>GO:0030669</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Endomembrane system</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Early endosome</CellLocal>
      <Ontology_ID>GO:0005769</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Endosome membrane</CellLocal>
      <Ontology_ID>GO:0010008</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Coated pit</CellLocal>
      <Ontology_ID>GO:0005905</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>External side of plasma membrane</CellLocal>
      <Ontology_ID>GO:0009897</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Integral to membrane</CellLocal>
      <Ontology_ID>GO:0016021</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Low-density lipoprotein particle</CellLocal>
      <Ontology_ID>GO:0034362</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane</CellLocal>
      <Ontology_ID>GO:0016020</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>LDLR</Gene_Name>
    <Gene_ID>3949</Gene_ID>
    <Genbank_ACCN>NM_000527</Genbank_ACCN>
    <Protein_ACCN>NP_000518</Protein_ACCN>
    <HGNC_ID>6547</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/3949</Gene_URL>
    <UCSC_ID>uc002mqk.4</UCSC_ID>
    <EMBL_ID>ENSG00000130164</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Hypercholesterolemia, Familial, Modifier of</Disease_Name>
      <Disease_Detail>Hypercholesterolemia</Disease_Detail>
      <Disease_DB>HYP574</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypercholesterolemia_familial_modifier_of?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyperalphalipoproteinemia</Disease_Name>
      <Disease_Detail>Hyperalphalipoproteinemia</Disease_Detail>
      <Disease_DB>HYP090</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperalphalipoproteinemia?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Atherosclerosis</Disease_Name>
      <Disease_Detail>Atherosclerosis</Disease_Detail>
      <Disease_DB>ATH003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/atherosclerosis?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypercholesterolemia</Disease_Name>
      <Disease_Detail>Hypercholesterolemia</Disease_Detail>
      <Disease_DB>HYP095</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypercholesterolemia?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cholesteryl Ester Storage Disease</Disease_Name>
      <Disease_Detail>Cholesteryl Ester Storage Disease</Disease_Detail>
      <Disease_DB>CHL074</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cholesteryl_ester_storage_disease?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyperlipoproteinemia Type 2</Disease_Name>
      <Disease_Detail>Hyperlipoproteinemia</Disease_Detail>
      <Disease_DB>HYP164</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperlipoproteinemia_type_2?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypertriglyceridemia</Disease_Name>
      <Disease_Detail>Hypertriglyceridemia</Disease_Detail>
      <Disease_DB>HYP117</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypertriglyceridemia?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Coronary Artery Disease in Familial Hypercholesterolemia, Protection Against</Disease_Name>
      <Disease_Detail>Coronary Artery Disease in Familial Hypercholesterolemia, Protection Against</Disease_Detail>
      <Disease_DB>CRN127</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/coronary_artery_disease_in_familial_hypercholesterolemia_protection_against?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyperlipoproteinemia Type Iii</Disease_Name>
      <Disease_Detail>Hyperlipoproteinemia</Disease_Detail>
      <Disease_DB>HYP011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperlipoproteinemia_type_iii?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ldlr-Related Familial Hypercholesterolemia, Autosomal Dominant</Disease_Name>
      <Disease_Detail>Ldlr-Related Familial Hypercholesterolemia, Autosomal Dominant</Disease_Detail>
      <Disease_DB>LDL002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ldlr_related_familial_hypercholesterolemia_autosomal_dominant?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Hyperlipidemia</Disease_Name>
      <Disease_Detail>Familial Hyperlipidemia</Disease_Detail>
      <Disease_DB>FML035</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_hyperlipidemia?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Defective Apolipoprotein B-100</Disease_Name>
      <Disease_Detail>Defective Apolipoprotein B-100</Disease_Detail>
      <Disease_DB>DFC001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/defective_apolipoprotein_b_100?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypobetalipoproteinemia</Disease_Name>
      <Disease_Detail>Hypobetalipoproteinemia</Disease_Detail>
      <Disease_DB>HYP027</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypobetalipoproteinemia?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Smith-Lemli-Opitz Syndrome</Disease_Name>
      <Disease_Detail>Smith-Lemli-Opitz Syndrome</Disease_Detail>
      <Disease_DB>SMT004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/smith_lemli_opitz_syndrome?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Chronic Progressive External Ophthalmoplegia</Disease_Name>
      <Disease_Detail>Chronic Progressive External Ophthalmoplegia</Disease_Detail>
      <Disease_DB>CHR095</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/chronic_progressive_external_ophthalmoplegia?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Primary Angle-Closure Glaucoma</Disease_Name>
      <Disease_Detail>Primary Angle-Closure Glaucoma</Disease_Detail>
      <Disease_DB>PRM024</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/primary_angle_closure_glaucoma?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lipoprotein Glomerulopathy</Disease_Name>
      <Disease_Detail>Lipoprotein Glomerulopathy</Disease_Detail>
      <Disease_DB>LPP002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lipoprotein_glomerulopathy?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Ldl Cholesterol Level Qtl2</Disease_Name>
      <Disease_Detail>Ldl Cholesterol Level Qtl2</Disease_Detail>
      <Disease_DB>LDL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/ldl_cholesterol_level_qtl2?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypoalphalipoproteinemia</Disease_Name>
      <Disease_Detail>Hypoalphalipoproteinemia</Disease_Detail>
      <Disease_DB>HYP121</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypoalphalipoproteinemia?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Pinguecula</Disease_Name>
      <Disease_Detail>Pinguecula</Disease_Detail>
      <Disease_DB>PNG001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/pinguecula?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Aortic Disease</Disease_Name>
      <Disease_Detail>Aortic Disease</Disease_Detail>
      <Disease_DB>ART017</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/aortic_disease?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Hypercholesterolemia</Disease_Name>
      <Disease_Detail>Familial Hypercholesterolemia</Disease_Detail>
      <Disease_DB>FML021</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_hypercholesterolemia?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypercholesterolemia, Familial, Due to Ldlr Defect, Modifier of</Disease_Name>
      <Disease_Detail>Hypercholesterolemia</Disease_Detail>
      <Disease_DB>HYP296</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypercholesterolemia_familial_due_to_ldlr_defect_modifier_of?search=LDLR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Common Cold</Disease_Name>
      <Disease_Detail>Common Cold</Disease_Detail>
      <Disease_DB>CMM005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/common_cold?search=LDLR#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>LDL RECEPTOR LIGAND-BINDING MODULE 5, CALCIUM-COORDINATING</PDB_Title>
      <PDB_ID>1AJJ</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1AJJ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular basis of familial hypercholesterolaemia from structure of LDL receptor module.</PubMed_Title>
      <Author>Fass, D., et al.</Author>
      <Journal>Nature(1997)388:691-693</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9262405?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>LDL RECEPTOR LIGAND-BINDING MODULE 6</PDB_Title>
      <PDB_ID>1D2J</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1D2J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure of the sixth LDL-A module of the LDL receptor.</PubMed_Title>
      <Author>North, C.L., et al.</Author>
      <Journal>Biochemistry(2000)39:2564-2571</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10704205?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution structure of LA45 from LDLR</PDB_Title>
      <PDB_ID>2LGP</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2LGP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The Structure, Dynamics, and Binding of the LA45 Module Pair of the Low-Density Lipoprotein Receptor Suggest an Important Role for LA4 in Ligand Release.</PubMed_Title>
      <Author>Guttman, M., et al.</Author>
      <Journal>Biochemistry(2011)50:11001-11008</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22091758?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>PCSK9:EGF-A complex</PDB_Title>
      <PDB_ID>3BPS</PDB_ID>
      <Resolution>2.41</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BPS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Molecular basis for LDL receptor recognition by PCSK9.</PubMed_Title>
      <Author>Kwon, H.J., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.Usa(2008)105:1820-1825</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18250299?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SOLUTION STRUCTURE AND BACKBONE DYNAMICS OF A CONCATEMER OF EGF-HOMOLOGY MODULES OF THE HUMAN LOW DENSITY LIPOPROTEIN RECEPTOR</PDB_Title>
      <PDB_ID>1HZ8</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HZ8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>NMR structure and backbone dynamics of a concatemer of epidermal growth factor homology modules of the human low-density lipoprotein receptor.</PubMed_Title>
      <Author>Kurniawan, N.D., et al.</Author>
      <Journal>J.Mol.Biol.(2001)311:341-356</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11478865?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>PCSK9:EGFA (pH 7.4)</PDB_Title>
      <PDB_ID>3GCX</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GCX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells.</PubMed_Title>
      <Author>McNutt, M.C., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:10561-10570</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19224862?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>PCSK9-DELTAC D374A MUTANT BOUND TO WT EGF-A OF LDLR</PDB_Title>
      <PDB_ID>2W2P</PDB_ID>
      <Resolution>2.62</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2W2P</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and Biochemical Characterization of the Wild Type Pcsk9/Egf-Ab Complex and Natural Fh Mutants.</PubMed_Title>
      <Author>Bottomley, M.J., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:1313</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19001363?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of a complex between domain V of beta2-glycoprotein I and the fourth ligand-binding module from LDLR determined with Haddock</PDB_Title>
      <PDB_ID>2KRI</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2KRI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Mode of interaction between beta2GPI and lipoprotein receptors suggests mutually exclusive binding of beta2GPI to the receptors and anionic phospholipids.</PubMed_Title>
      <Author>Lee, C.J., et al.</Author>
      <Journal>Structure(2010)18:366-376</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20223219?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>WT PCSK9-DELTAC BOUND TO WT EGF-A OF LDLR</PDB_Title>
      <PDB_ID>2W2M</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2W2M</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and Biochemical Characterization of the Wild Type Pcsk9/Egf-Ab Complex and Natural Fh Mutants.</PubMed_Title>
      <Author>Bottomley, M.J., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:1313</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19001363?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation</PDB_Title>
      <PDB_ID>3P5C</PDB_ID>
      <Resolution>4.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3P5C</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>SOLUTION STRUCTURE AND BACKBONE DYNAMICS OF A CONCATEMER OF EGF-HOMOLOGY MODULES OF THE HUMAN LOW DENSITY LIPOPROTEIN RECEPTOR</PDB_Title>
      <PDB_ID>1I0U</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1I0U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>NMR structure and backbone dynamics of a concatemer of epidermal growth factor homology modules of the human low-density lipoprotein receptor.</PubMed_Title>
      <Author>Kurniawan, N.D., et al.</Author>
      <Journal>J.Mol.Biol.(2001)311:341-356</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11478865?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR STRUCTURE OF A CONCATEMER OF THE FIRST AND SECOND LIGAND-BINDING MODULES OF THE HUMAN LDL RECEPTOR</PDB_Title>
      <PDB_ID>1F5Y</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1F5Y</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>NMR structure of a concatemer of the first and second ligand-binding modules of the human low-density lipoprotein receptor.</PubMed_Title>
      <Author>Kurniawan, N.D., et al.</Author>
      <Journal>Protein Sci.(2000)9:1282-1293</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10933493?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>PCSK9-DELTAC D374Y MUTANT BOUND TO WT EGF-A OF LDLR</PDB_Title>
      <PDB_ID>2W2O</PDB_ID>
      <Resolution>2.62</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2W2O</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and Biochemical Characterization of the Wild Type Pcsk9/Egf-Ab Complex and Natural Fh Mutants.</PubMed_Title>
      <Author>Bottomley, M.J., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:1313</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19001363?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>PCSK9:EGFA(H306Y)</PDB_Title>
      <PDB_ID>3GCW</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GCW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells.</PubMed_Title>
      <Author>McNutt, M.C., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:10561-10570</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19224862?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the LDL Receptor YWTD-EGF Domain Pair</PDB_Title>
      <PDB_ID>1IJQ</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IJQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair.</PubMed_Title>
      <Author>Jeon, H., et al.</Author>
      <Journal>Nat.Struct.Biol.(2001)8:499-504</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11373616?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>PCSK9-DELTAC D374H MUTANT BOUND TO WT EGF-A OF LDLR</PDB_Title>
      <PDB_ID>2W2Q</PDB_ID>
      <Resolution>2.33</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2W2Q</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and Biochemical Characterization of the Wild Type Pcsk9/Egf-Ab Complex and Natural Fh Mutants.</PubMed_Title>
      <Author>Bottomley, M.J., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:1313</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19001363?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Extracellular domain of the LDL receptor</PDB_Title>
      <PDB_ID>1N7D</PDB_ID>
      <Resolution>3.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1N7D</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the LDL receptor extracellular domain at endosomal pH</PubMed_Title>
      <Author>Rudenko, G., et al.</Author>
      <Journal>Science(2002)298:2353-2358</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12459547?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THREE-DIMENSIONAL STRUCTURE OF A CYSTEINE-RICH REPEAT FROM THE LOW-DENSITY LIPOPROTEIN RECEPTOR</PDB_Title>
      <PDB_ID>1LDL</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LDL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Three-dimensional structure of a cysteine-rich repeat from the low-density lipoprotein receptor.</PubMed_Title>
      <Author>Daly, N.L., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1995)92:6334-6338</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7603991?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>WT PCSK9-DELTAC BOUND TO EGF-A H306Y MUTANT OF LDLR</PDB_Title>
      <PDB_ID>2W2N</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2W2N</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and Biochemical Characterization of the Wild Type Pcsk9/Egf-Ab Complex and Natural Fh Mutants.</PubMed_Title>
      <Author>Bottomley, M.J., et al.</Author>
      <Journal>J.Biol.Chem.(2009)284:1313</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19001363?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SECOND REPEAT OF THE LDL RECEPTOR LIGAND-BINDING DOMAIN</PDB_Title>
      <PDB_ID>1LDR</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1LDR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Three-dimensional structure of the second cysteine-rich repeat from the human low-density lipoprotein receptor.</PubMed_Title>
      <Author>Daly, N.L., et al.</Author>
      <Journal>Biochemistry(1995)34:14474-14481</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7578052?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Solution structure of the LA7-EGFA pair from the LDL receptor</PDB_Title>
      <PDB_ID>1XFE</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1XFE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Cooperation between Fixed and Low pH-Inducible Interfaces Controls Lipoprotein Release by the LDL Receptor</PubMed_Title>
      <Author>Beglova, N., et al.</Author>
      <Journal>Mol.Cell(2004)16:281-292</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15494314?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The X-ray Crystal Structure of PCSK9 in Complex with the LDL receptor</PDB_Title>
      <PDB_ID>3M0C</PDB_ID>
      <Resolution>7.01</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3M0C</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The X-ray Crystal Structure of PCSK9 in Complex with the LDL receptor</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation</PDB_Title>
      <PDB_ID>3P5B</PDB_ID>
      <Resolution>3.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3P5B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Structure of a Complex Between the Pair of the LDL Receptor Ligand-Binding Modules 3-4 and the Receptor Associated Protein (RAP).</PDB_Title>
      <PDB_ID>2FCW</PDB_ID>
      <Resolution>1.26</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FCW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of an LDLR-RAP Complex Reveals a General Mode for Ligand Recognition by Lipoprotein Receptors</PubMed_Title>
      <Author>Fisher, C., et al.</Author>
      <Journal>Mol.Cell(2006)22:277-283</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16630895?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR STRUCTURE OF THE SIXTH LIGAND-BINDING MODULE OF THE LDL RECEPTOR</PDB_Title>
      <PDB_ID>1F8Z</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1F8Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Three-dimensional NMR structure of the sixth ligand-binding module of the human LDL receptor: comparison of two adjacent modules with different ligand binding specificities.</PubMed_Title>
      <Author>Clayton, D., et al.</Author>
      <Journal>FEBS Lett.(2000)479:118-122</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10981718?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>NMR STUDY OF A PAIR OF LDL RECEPTOR CA2+ BINDING EPIDERMAL GROWTH FACTOR-LIKE DOMAINS, 20 STRUCTURES</PDB_Title>
      <PDB_ID>1HJ7</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1HJ7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution Structure of the Ldl Receptor Egf-Ab Pair: A Paradigm for the Assembly of Tandem Calcium Binding Egf Domains</PubMed_Title>
      <Author>Saha, S., et al.</Author>
      <Journal>Structure(2001)9:451</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11435110?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05160</Pathway_ID>
      <Pathway_Title>Hepatitis C</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04913</Pathway_ID>
      <Pathway_Title>Ovarian steroidogenesis</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05145</Pathway_ID>
      <Pathway_Title>Toxoplasmosis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04976</Pathway_ID>
      <Pathway_Title>Bile secretion</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Digestive system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Small proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.h.bc.b.b.b.html</SCOP_URL>
    <CATH_Class>Class 4: Few Secondary Structures</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1d2j</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Type>Open-Close</Site_Type>
    </AllostericSite>
  </AllostericSite_List>
  <Allosteric_Pathway>
    <Pathway>H562@@H586, H190, E187@@D203@@E208 </Pathway>
    <Method>Mutations</Method>
    <Verified__Residue>H190, H562, H586</Verified__Residue>
    <PubMed_Title>Zhao Z, et al. J Biol Chem. 2008,283(39):26528-26537.</PubMed_Title>
    <PubMed_ID>18677035</PubMed_ID>
    <is__ref__img>No</is__ref__img>
    <is__display>Yes</is__display>
    <in__pathway__browse>Yes</in__pathway__browse>
  </Allosteric_Pathway>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>